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NOD-scid IL-2Rγ−/−miceHumanized Bone marrow/Liver/Thymus (BLT) mice recapitulate the mucosal transmission of HIV, permitting
study of early events in HIV pathogenesis and evaluation of preexposure prophylaxis methods to inhibit HIV
transmission. Human hematopoiesis is reconstituted in NOD-scid mice by implantation of human fetal liver
and thymus tissue to generate human T cells plus intravenous injection of autologous liver-derived CD34+
hematopoietic stem cells to engraft the mouse bone marrow. In side-by-side comparisons, we show that
NOD-scidmice homozygous for a deletion of the IL-2Rγ-chain (NOD-scid IL-2Rγ−/−) are far superior to NOD-
scidmice in both their peripheral blood reconstitutionwithmultiple classes of human leukocytes (e.g., a mean
of 182 versus 14 CD4+ T cells per μl 12 weeks after CD34+ injection) and their susceptibility to intravaginal
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The development of small animal models for the study of HIV
infection is important for the study of HIV prophylaxis and disease
pathogenesis.Mousemodels that recapitulate themucosal transmission
of HIV permit the study of early events in HIV pathogenesis and
evaluation of preexposure prophylaxis methods to inhibit HIV trans-
mission. Humanized Bone marrow/Liver/Thymus (BLT) mice, devel-
oped and reported by Lan et al. (2006) and Melkus et al. (2006),
represent such a key model. In these mice, human hematopoiesis is
reconstituted in NOD-scidmice in which human fetal liver and thymus
tissue (Thy/Liv) are implanted under the kidney capsule to produce a
thymic organoid that supports the development of human T cells. Three
weeks after tissue implantation, mice are irradiated, and puriﬁed fetal-
liver-derived human CD34+ hematopoietic stem/progenitor cells
(HSPCs) are injected intravenously. This method leads to robust
reconstitution of human leukocytes in the mouse peripheral blood
and lymphoid organs and importantly, BLT mice are susceptible tomucosal HIV challenge by both intrarectal (Denton et al., 2010; Sun et
al., 2007) and intravaginal exposure (Denton et al., 2008). An alternative
humanized mouse model with robust reconstitution of human
leukocytes, the Rag-hu mouse, has been reported to be susceptible to
intravaginal and intrarectal HIV challenge by one group of investigators
(Berges et al., 2008; Neff et al., 2010) but resistant to intrarectal HIV
transmission by another group (Hofer et al., 2008). These mice are not
implanted with fetal tissue and are reconstituted as neonates with
CD34+ HSPCs injected intrahepatically after irradiation.
In previous work, both NOD-scid and NOD-scid mice homozygous
for a deletion of the IL-2R γ-chain (NOD-scid IL-2Rγ−/−, also called
NSG) (Shultz et al., 2005) have been used as hosts for the BLT model,
with no differences reported between the strains in the extent of
human immune system reconstitution (Brainard et al., 2009; Denton
et al., 2010). In our initial studies with NOD-scid mice, however, we
observed poor reconstitution and susceptibility to mucosal HIV
challenge. We therefore decided to directly compare age-matched
NOD-scid with NSG mice engrafted with the same human tissues and
CD34+ HSPCs, in a strategy similar to that used recently to compare
three different IL-2Rγ−/− mouse strains (Brehm et al., 2010). The IL-
2R γ-chain is a crucial component of the high-afﬁnity receptors for IL-
2, IL-4, IL-7, IL-9, IL-15, and IL-21 and is required for signaling through
these receptors (Shultz et al., 2007; Sugamura et al., 1996). Its absence
leads to severe impairment in T- and B-cell development and function,
Table 1
Proportion of viremic BLT mice 4 weeks after intravaginal HIV inoculation.
Cohort CD45+Lin-1−CD34+
HSPCs injected per mouse
CD45+Lin-1−CD34+CD38−c-kit+
cells injected per mouse
HIV strain
(TCID50a per mouse)
Mouse strain p valueb
NOD-scid–BLT
(viremicc/total)
NSG–BLT
(viremic/total)
A 606,000 autologous 74,000 81A-G 0/9 (0%) 6/7 (85%) 0.0009
(50×106)
B 206,000 allogeneic 25,000 81A-G 0/14 (0%) 10/13 (77%) b0.0001
(50×106)
C 420,000 autologous 54,000 JR-CSF 3/14 (21%) 9/10 (90%) 0.0028
(0.5×106)
D 310,000 autologous 15,000 JR-CSF 2/9 (22%) 7/8 (88%) 0.0152
(0.5×106)
Total 5/46 (11%) 32/38 (84%) b0.0001
a TCID50: 50% tissue culture infectious doses, as assessed by limiting dilution assay in PHA-activated PBMC with supernatant p24 detection 7 days after inoculation.
b p values determined by Fisher's Exact test.
c Viremic deﬁned as N1.9 log10 copies HIV RNA per 100 μl of mouse plasma (assay detection limit).
155C.A. Stoddart et al. / Virology 417 (2011) 154–160and completely prevents NK-cell development (Cao et al., 1995;
DiSanto et al., 1995; Ohbo et al., 1996; Shultz et al., 2007). In four such
side-by-side comparisons, we found that NSG mice were far superior
to NOD-scid mice in both their peripheral blood reconstitution
with human leukocytes and their susceptibility to intravaginal HIV
exposure.
Results
Four cohorts of BLTmice (A, B, C, and D) were each implanted with
human tissues from a single donor into both types of mice in side-by-
side comparisons. CD34+ HSPCs were puriﬁed from human fetal liver0 50K 100K 150K 200K 250K
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Fig. 1. Phenotypic analysis of CD34-enriched fetal liver cells. (A) Cryopreserved CD34-enric
cytometry. Isolated fetal liver cells were stained to determine the frequency of CD34+ cells th
(top) and c-kit expression (bottom). The frequency of CD45+Lin-1−CD34+CD38−c-kit+ (poby positive selection, cryopreserved, and injected into irradiated mice
3 weeks after Thy/Liv implantation. Cohorts A, C, and D were injected
with HSPCs isolated from the autologous fetal liver; cohort B was
injected with allogeneic HSPCs (200,000–600,000 viable CD45+Lin-
1−CD34+ HSPCs per mouse) (Table 1). The HSPCs were further
evaluated for CD38 and c-kit expression, and the percentage of
injected fetal liver cells that were CD45+Lin-1−CD34+CD38−c-kit+,
and thus potential long-term SCID-repopulating cells (SRCs) (Dick et
al., 1997), was 3–10% (15,000–74,000 SRC per mouse) (Fig. 1).
At the time of HIV inoculation, 12 weeks after CD34+ HSPC
injection, NSG–BLT mice had substantially higher levels of human
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Fig. 3. The percentage of human CD45+ cells in the leukocyte gate was artiﬁcially high
for mice that were highly leukopenic for mouse leukocytes. For instance, mouse #14
had a high percentage of human CD45+ reconstitution (79.8%) but comparable
numbers of human CD45+ cells to mouse #17, which had an apparently low percentage
of human CD45+ reconstitution (19.8%). The apparent difference in human reconsti-
tution, expressed as percentage, was largely driven by the large difference in murine
CD45+ cells between mouse #14 (64 cells/μl) and mouse #17 (798 cells/μl).
157C.A. Stoddart et al. / Virology 417 (2011) 154–160mice (Fig. 2). NSG–BLT mice in all four cohorts had a mean of 13 times
more human CD4+ T cells per μl of blood, 8 timesmore CD8+ T cells, 4
times more monocytes, 3 times more B cells, and similar numbers of
human NK cells and neutrophils. The cohort engrafted with allogeneic
CD34+ cells (cohort B) had essentially no detectable B cells in the
peripheral blood which made their overall reconstitution, as shown
by the numbers of CD45+ cells in Fig. 2B, appear lower than for the
three cohorts engrafted with autologous CD34+ cells. The numbers of
T cells in the peripheral bloodwas similar for all four cohorts.We have
not yet determined whether the lack of B cells in cohort B was the
result of using allogeneic CD34+ cells.
We found that the absolute count of these cells was a more useful
measure of the level of human reconstitution thanwas the percentage
of human CD45+ cells in the leukocyte gate because the latter value
was heavily inﬂuenced by the number of mouse CD45+ cells present
in the blood. In mice that were highly leukopenic in terms of mouse
leukocytes, the percentage of human CD45+was often artiﬁcially high
and not reﬂective of the absolute counts of human CD45+ cells
(Fig. 3). For all four cohorts, we obtained a mean of 182 (range of 20–
1044) CD4+ T cells per μl in NSG–BLTmice versus 14 (range of 0–240)
CD4+ T cells per μl in NOD-scid BLT mice. The numbers of HPSCs
injected into each mouse were within the range of injected cells
(200,000–2.5×106) reported byMelkus et al. (2006) for NOD-scid BLT
mice. There was no correlation between the numbers of CD45+Lin-
1−CD34+CD38−c-kit+ cells injected and the levels of human CD45+
cells in the peripheral blood 12 weeks after injection for either mouse
strain (data not shown).
Most NSG–BLT mice became viremic by 4 weeks after intravaginal
HIV exposure, whereas only a few NOD-scid–BLT mice became
productively infected (Table 1). Viral loads in NSG–BLT mice reached
a maximum of 4.7 log10 copies of HIV RNA per 100 µl of plasma, and
maximal viral loads in NOD-scid–BLT mice were N10-fold lower
(Fig. 4). Interestingly, there was no correlation between viral loads
4 weeks after inoculation and numbers of human CD4+ T cells inFig. 2. Reconstitution with multiple classes of human leukocytes in peripheral blood. (A) Tr
gated region was used to calculate the absolute number of cells per μl inside the gate. The c
events per unit volume of whole blood. Human whole blood control (top panels) was use
neutrophils, monocytes, and lymphocytes (second from left); B cells, T cells, and NK cells (th
blood were applied to whole blood from NOD-scid BLT and NSG–BLT mice (bottom). (B) Th
Trucount analysis for each individual cohort (A–D) 12 weeks after injection of fetal liver deri
of CD45+ leukocytes and of CD4+ T cells relative to NOD-scid mouse recipients. (C) Absolu
(CD56+), monocytes, and neutrophils were combined from all four cohorts of BLT mice. On
lineages than did NOD-scid recipients. (**pb0.01, ***pb0.001, Mann–Whitney U-test).peripheral blood at the time of inoculation in NSG–BLT mice. NOD-
scid–BLT mice that were not viremic by 4 weeks after inoculation did
not become viremic when followed for up to 12 weeks after
intravaginal JR-CSF inoculation, and all successfully infected NSG–
BLT mice became viremic by 4 weeks (Fig. 5). The greater suscepti-
bility of NSG–BLT mice to intravaginal HIV infection mice appeared to
correlatewith the greater numbers of human T cells, including CD4+ T
cells, in the vaginalmucosawithin both the epithelium and the lamina
propria of these mice compared to NOD-scid–BLT mice (Fig. 6).
Discussion
The NOD-scid xenotransplantation model has been described as
the “gold standard” for assessing human hematopoietic stem cell
activity, and a number of advancements have been reported to further
improve engraftment, such as depletion of NK cells with anti-CD122
Ab, direct intrafemoral injection of HSPCs, and deletion or truncation
of IL-2Rγ (McDermott et al., 2010). A recent report directly comparing
overall engraftment and multilineage differentiation of lineage-
depleted human umbilical cord blood cells after intrafemoral injection
showed superior engraftment in the bone marrow and spleen of NSG
mice compared to NOD-scid mice as well as improved detection of
SRCs at limiting dilutions (McDermott et al., 2010). Here, we extend
these observations by showing superior peripheral blood reconstitu-
tion with multiple classes of human leukocytes and correspondingly
greater susceptibility to intravaginal HIV exposure in NSG–BLT mice
compared to NOD-scid–BLT mice. The BLT mouse model we employed
differs in a number of important respects from the SRC-detection
model described above, including the presence of a human Thy/Liv
organoid under the kidney capsule, intravenous injection of much
higher numbers of human fetal liver-derived HSPCs, and successful
engraftment deﬁned by large numbers (N50 cells per μl) of human
CD4+ T cells in the peripheral blood rather than simple detection of
CD45+ cells over isotype control staining in bone marrow. Despite
these differences, however, both models show superior human
immune reconstitution in NSGmice. Although the precise mechanism
by which NSG mice experience more robust reconstitution has not
been deﬁned, it is likely to be the consequence of severe defects in NK
cell activity resulting from the lack of IL-2R signaling (Shultz et al.,
2005). This explanation is supported by the lack of improved human
HSPC engraftment in NSG mice treated with an anti-CD122 Ab that
inhibits NK cell activity (McDermott et al., 2010). An alternative
explanation is that IL-2Rγ−/− murine hematopoietic progenitors in
NSG mice cannot compete as efﬁciently with the injected human
HSPCs for bone marrow niches after irradiation, but our preliminary
data comparing murine HSPC regrowth in bone marrow of unmani-
pulated NSG and NOD-scid mice after irradiation show no signiﬁcant
differences (data not shown).
We were surprised that so few (11% overall) NOD-scid BLT mice
became viremic after intravaginal HIV exposure in our study as
Denton et al. (2008) reported that 7 of 8 BLT mice (88%) became
viremic by 50 days after intravaginal JR-CSF inoculation (with 63%
viremic by 28 days). The authors do not specify whether NOD-scid or
NSG mice were used in that study. In a just-published report by the
same group, 13 of 16 total mice (81%) became viremic after
intravaginal exposure to JR-CSF (Denton et al., 2011). The authorsucount quantiﬁcation of peripheral blood leukocytes. The number of events within any
alculation uses the known number of gated beads in a ratio with the number of gated
d to set the gates for enumeration of total human and mouse leukocytes (left panel);
ird from left); and CD4+ and CD8+ T cells (right panel). Gates set using human whole
e absolute number of human leukocytes (CD45+) and CD4+ T cells was determined by
ved HSPCs. NSG recipient mice from all four cohorts displayed greatly elevated numbers
te numbers of CD45+ leukocytes, B cells (CD19+), CD4+ T cells, CD8+ T cells, NK cells
average, NSG recipients had much greater numbers of each of these human leukocyte
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Fig. 4. Overall lack of correlation between human CD4+ T cells in peripheral blood at the time of intravaginal HIV inoculation and HIV viremia 4 weeks later. Cohorts A and B were
inoculated with HIV 81A-G, and cohorts C and D were inoculated with JR-CSF. HIV RNA in mouse plasma was quantiﬁed by bDNA assay. Data were analyzed by Spearman's rank
correlation coefﬁcient and show no correlation between CD4+ T-cell count and HIV viremia, except for NOD-scid mice in cohort C.
158 C.A. Stoddart et al. / Virology 417 (2011) 154–160state that NOD-scid or NSG mice were used to prepare BLT mice and
do not mention a difference in HIV susceptibility between the strains.
In the NOD-scid BLT mice that we followed until 12 weeks after
inoculation, no additional mice became viremic after the ﬁrst 4 weeks
(Fig. 5). We have no clear explanation for this discrepancy. For cohorts
C and D, we inoculated the sameHIV isolate (JR-CSF) at an even higher
inoculum size (500,000 versus 90,000 TCID50) than in the 2008 study.
We obtained the NOD-scid mice from a different source (Taconic)
than reported by Denton et al. (The Jackson Laboratory), but this
seems an unlikely explanation for the difference in susceptibility
to intravaginal HIV infection in the BLT mice prepared from these
animals.
The ultimate goal of our BLT model studies is reproducible
susceptibility to intravaginal HIV exposure for the study of early
events in HIV pathogenesis as well as for preclinical evaluation of HIV
microbicides and oral preexposure prophylaxis. The superior human
leukocyte reconstitution and susceptibility to vaginal HIV transmis-
sion that we have demonstrated for NSG mice support their useFig. 5. NOD-scid–BLT mice that were not viremic by 4 weeks after inoculation did not
become viremic when followed for up to 12 weeks after intravaginal JR-CSF inoculation,
and all successfully infected NSG–BLT mice became viremic by 4 weeks after
inoculation. Data shown are for all mice in cohort B (14 NOD-scid–BLT mice and 13
NSG mice). Similar results were obtained for cohorts A and C; all mice in cohort D were
euthanized for tissue collection at 4 weeks. The dotted line is the limit of HIV RNA
detection (1.9 log10 copies per 100 μl mouse plasma).(as well as the similar IL2Rγ−/− NOG mouse) (Ito et al., 2002) as the
“gold standard” for humanized BLT mice, as has been proposed for
their use in human HSPC and cancer stem cell research (McDermott
et al., 2010).
Materials and methods
BLT mouse generation
BLT mice were produced as described by Melkus et al. (2006)
by implanting 1-mm3 pieces of human fetal liver and thymus
under the kidney capsule of 11–15-week-old female NOD-scid
(NOD/MrkBomTac-Prkdcscid, Taconic) and female NSG mice (NOD.
Cg-PrkdcscidIl2rgtm1Wjl/SzJ, The Jackson Laboratory). Each cohort (A, B,
C, and D) was implanted with human tissues from a single donor into
both types of mice in side-by-side comparisons. CD34+ HSPCs were
puriﬁed from human fetal liver by collagenase dispersion, isolation of
mononuclear cells by centrifugation over NycoPrep 1.077 (Axis-
Shield), and magnetic bead selection for CD34+ cells (Miltenyi
Biotech). HSPCs were cryopreserved in 90% FBS/10% DMSO and
stored in liquid nitrogen until injection into mice 3 weeks after
Thy/Liv implantation. Mice were conditioned by 225 cGy γ-
irradiation from a cesium-137 source (Gammacell 3000, Best
Theratronics) 30 h before HSPC injection into the tail vein. Cohorts
A, C, and D were injected with HSPCs isolated from the autologous
fetal liver; cohort B was injected with allogeneic HSPCs. A portion of
the thawed cells were immunophenotyped by ﬂow cytometry to
determine the frequency of CD34+ cells that were CD45+ and Lin-1−
(lineage cocktail 1, BD Biosciences), and 200,000–600,000 of these
viable CD45+Lin-1−CD34+ HSPCs were injected into each mouse
(Fig. 1 and Table 1). The CD34+ cells were further evaluated for CD38
and c-kit expression, and the percentage of injected fetal liver cells
that were CD45+Lin-1−CD34+CD38−c-kit+, and thus potential
long-term SCID-repopulating cells (SRCs) (Dick et al., 1997), was
3–10%. Animal protocols were approved by the UCSF Institutional
Animal Care and Use Committee.
Fig. 6. Formaldehyde-ﬁxed, frozen/OCT-embedded tissue sections of NSG control (A, B), NOD-scid–BLT (C, D) and NSG–BLT (E, F) mice immunostained for human CD3 and CD4 with
nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI). BLT mice were from cohort D. Original magniﬁcation, ×200; inset, ×400. Parafﬁn-embedded vaginal tissue sections of
NOD-scid–BLT (G) and NSG–BLT (H) mice stained with H&E. Original magniﬁcation, ×100; inset, ×400. LP, lamina propria, Ep, epithelium, Lu, vaginal lumen.
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Twelve weeks after HSPC injection, peripheral blood was collected
from the retroorbital sinus for assessment of human leukocyte
reconstitution, and mice were inoculated intravaginally with 20 μl of
the R5 HIV molecular clones 81A (Chesebro et al., 1991, 1992; Toohey
et al., 1995; Walter et al., 2005) or JR-CSF (Cann et al., 1990; Haltiner
et al., 1985; Koyanagi et al., 1987) delivered with an unmodiﬁed
200-μl yellow plastic pipette tip with no intended abrasion or trauma.
We chose HIV 81A because we and others had studied this clone
previously in SCID-hu Thy/Liv mice (Berkowitz et al., 2000; Stoddart
et al.); JR-CSF was chosen because Denton et al. (2008) reported this
clone to productively infect BLT mice after intravaginal exposure with
90,000 tissue culture infectious units. p81A-4, which contains the V1–
V3 env regions of Ba-L in an NL4-3 background, was altered by site-
directed mutagenesis to match the consensus sequence (and thereby
restore sensitivity to the HIV fusion inhibitor T-20) at amino acid
position 36 (aspartic acid replaced by glycine) of gp41, creating HIV
81A gp41/D36G (81A-G) (Greenberg and Cammack, 2004; Stoddart
et al., 2008). HIV inocula were generated by lipofectamine transfec-
tion of 293 T cells with plasmid DNA and concentrated N100-fold by
ultracentrifugation through a 30% sucrose cushion for 2 h at
120,000 ×g.
Flow cytometry and Trucount enumeration
Human leukocyte reconstitution was assessed by ﬂow cytometry
using Trucount tube (BD Biosciences) enumeration to determine the
absolute number of human B cells, CD4+ and CD8+ T cells, mono-
cytes, NK cells, and neutrophils per μl of blood (Fig. 2). Human CD45-
speciﬁc (Caltag) and mouse CD45-speciﬁc (BD Biosciences) anti-
bodies were used to separate mouse from human leukocytes. Human
CD45+ cells were typed using antibodies speciﬁc for CD3 (BeckmanCoulter), CD8 (Invitrogen) CD4, CD14, CD19, and CD56 (Biolegend).
Data analysis was performed using FlowJo software (TreeStar).
Viral load quantiﬁcation and histochemistry
Bloodwas collected4, 6, 8, 10, and 12 weeks afterHIV inoculation for
quantiﬁcation of viral load in plasma by branched DNA assay (VERSANT
HIV RNA 3.0, Siemens Healthcare) according to the manufacturer's
instructions. Mouse vaginas were ﬁxed in formalin for parafﬁn
embedding andH&E staining or in 4% paraformaldehyde for embedding
and freezing in optimal-cutting-temperature (OCT) compound and
immunohistochemistry for human CD3 (BD Pharmingen) and CD4
(Abcam).
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